中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
CHINESE JOURNAL OF OSTEOPOROSIS
2014年
2期
189-191
,共3页
骨化三醇%骨代谢%骨密度%老年女性%2型糖尿病
骨化三醇%骨代謝%骨密度%老年女性%2型糖尿病
골화삼순%골대사%골밀도%노년녀성%2형당뇨병
Calcitriol%Bone metabolism%Bone mineral density%Senile female%Type 2 diabetes mellitus
目的：探讨骨化三醇联合钙尔奇D对老年女性2型糖尿病患者骨代谢的影响。方法2011年7月至2012年6月本院老年科及内分泌科45例≥65岁女性糖尿病住院患者，其中对照组23例，患者每晚口服1片钙尔奇D（疗程6个月），每片含碳酸钙1.5 g（相当于钙600 mg，维生素D3125IU）；治疗组22例，患者每晚口服骨化三醇0.25μg联合1片钙尔奇D（疗程6个月），两组患者基础用药无明显差异，具有可比性。对比分析两组患者体重，腰围，BMI，血清血糖，血脂，肾功能，血钙，血磷，碱性磷酸酶，糖化血红蛋白，尿微量白蛋白/尿肌酐，Ⅰ型胶原羧基末端肽（CTx），Ⅰ型胶原氨基末端肽（PINP），右跟骨超声骨密度。结果两组患者体重、腰围、BMI，血糖、血脂、肾功能，糖化血红蛋白，尿微量白蛋白/尿肌酐参数均无统计学差异；而骨化三醇联合钙尔奇D治疗组患者的血钙水平明显高于对照组，差异有统计学意义（2.51±0.16 vs．2.08±0.15， P＜0.05）；CTx明显低于对照组，差异有统计学意义（0.385±0.28 vs．0.644±0.31， P＜0.01）；跟骨超声骨密度明显高于对照组，差异有统计学意义（0.618±0.108 vs．0.402±0.133， P＜0.05）。结论骨化三醇联合钙尔奇D明显降低老年女性2型糖尿病患者的骨吸收，改善骨代谢，增加骨密度。
目的：探討骨化三醇聯閤鈣爾奇D對老年女性2型糖尿病患者骨代謝的影響。方法2011年7月至2012年6月本院老年科及內分泌科45例≥65歲女性糖尿病住院患者，其中對照組23例，患者每晚口服1片鈣爾奇D（療程6箇月），每片含碳痠鈣1.5 g（相噹于鈣600 mg，維生素D3125IU）；治療組22例，患者每晚口服骨化三醇0.25μg聯閤1片鈣爾奇D（療程6箇月），兩組患者基礎用藥無明顯差異，具有可比性。對比分析兩組患者體重，腰圍，BMI，血清血糖，血脂，腎功能，血鈣，血燐，堿性燐痠酶，糖化血紅蛋白，尿微量白蛋白/尿肌酐，Ⅰ型膠原羧基末耑肽（CTx），Ⅰ型膠原氨基末耑肽（PINP），右跟骨超聲骨密度。結果兩組患者體重、腰圍、BMI，血糖、血脂、腎功能，糖化血紅蛋白，尿微量白蛋白/尿肌酐參數均無統計學差異；而骨化三醇聯閤鈣爾奇D治療組患者的血鈣水平明顯高于對照組，差異有統計學意義（2.51±0.16 vs．2.08±0.15， P＜0.05）；CTx明顯低于對照組，差異有統計學意義（0.385±0.28 vs．0.644±0.31， P＜0.01）；跟骨超聲骨密度明顯高于對照組，差異有統計學意義（0.618±0.108 vs．0.402±0.133， P＜0.05）。結論骨化三醇聯閤鈣爾奇D明顯降低老年女性2型糖尿病患者的骨吸收，改善骨代謝，增加骨密度。
목적：탐토골화삼순연합개이기D대노년녀성2형당뇨병환자골대사적영향。방법2011년7월지2012년6월본원노년과급내분비과45례≥65세녀성당뇨병주원환자，기중대조조23례，환자매만구복1편개이기D（료정6개월），매편함탄산개1.5 g（상당우개600 mg，유생소D3125IU）；치료조22례，환자매만구복골화삼순0.25μg연합1편개이기D（료정6개월），량조환자기출용약무명현차이，구유가비성。대비분석량조환자체중，요위，BMI，혈청혈당，혈지，신공능，혈개，혈린，감성린산매，당화혈홍단백，뇨미량백단백/뇨기항，Ⅰ형효원최기말단태（CTx），Ⅰ형효원안기말단태（PINP），우근골초성골밀도。결과량조환자체중、요위、BMI，혈당、혈지、신공능，당화혈홍단백，뇨미량백단백/뇨기항삼수균무통계학차이；이골화삼순연합개이기D치료조환자적혈개수평명현고우대조조，차이유통계학의의（2.51±0.16 vs．2.08±0.15， P＜0.05）；CTx명현저우대조조，차이유통계학의의（0.385±0.28 vs．0.644±0.31， P＜0.01）；근골초성골밀도명현고우대조조，차이유통계학의의（0.618±0.108 vs．0.402±0.133， P＜0.05）。결론골화삼순연합개이기D명현강저노년녀성2형당뇨병환자적골흡수，개선골대사，증가골밀도。
Objective To investigate the effect of calcitriol combined with Caltrate D on bone metabolism in senile female patients with type 2 diabetes mellitus (T2DM).Methods Forty-five senile female patients with T2DM, who were hospitalized in the Department of Geriatrics and the Department of Endocrinology in our hospital from July 2011 to June 2012, with an age over 65 years old, were selected.Among them, 23 patients in the control group received an oral medication of 1 tablet of Caltrate D for 6 months, and each tablet contained 1.5g calcium carbonate, equivalent calcium to 600 mg with vitamin D3 125IU.Twenty-two patients in the treatment group took an oral medication of 0.25μg calcitriol combined with 1 tablet of Caltrate D for 6 months.The basic drug treatment in both groups had no significant difference, showing comparability.The differences of body weight, waist circumference, body mass index (BMI), kidney function, quantitative of urinary albumin, glycosylated hemoglobin (HbA1c), serum levels of glucose, lipid, calcium ( Ca), phosphorus (P), alkali phosphatase ( AKP), C-telopeptide of type I collagen (CTx), procollagen I N-terminal propeptide (PINP), and the bone mineral density (BMD) of the right calcaneal were compared and analyzed.Results No significant difference of weight, waist circumference, BMI, kidney function, quantitative of urinary albumin, HbA1c, and serum levels of glucose and lipid between both groups was observed.However, the serum level of calcium in the treatment group was significantly higher than that in the control group (2.51 ±0.16 vs.2.08 ±0.15, P<0.05).And the serum level of CTx was significantly lower than that in the control group (0.385 ±0.28 vs.0.644 ±0.31, P<0.01).BMD of the calcaneus in the treatment group was significantly higher than that in the control group (0.618 ±0.108 vs.0.402 ±0.133, P<0.05).Conclusion The application of calcitriol combined with Caltrate D can significantly reduce bone resorption, improve bone metabolism, and increase BMD in senile female patients with T2DM.
